SCHEMBL4352334

SCHEMBL4352334

COc1ccc(Oc2ncnc3c2cnn3C2CCN(C(=O)O)CC2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.62
FLT3 P36888 2/20 0.46
POLB P06746 4/20 0.41
RAB9A P51151 3/20 0.41
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41
SLC2A1 P11166 1/20 0.41
SLC2A2 P11168 1/20 0.41
SLC2A3 P11169 1/20 0.41
KDR P35968 2/20 0.40
PDE9A O76083 2/20 0.40
CYP2C9 P11712 1/20 0.40
PDGFRA P16234 1/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
SRC P12931 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1128417 0.91 CYP3A4 (0.60) CYP3A4FLT3KDM4ESLC2A1SLC2A2
SCHEMBL4366581 0.90 CYP3A4 (0.56) CYP3A4FLT3RAB9AKDM4ENPC1
SCHEMBL4360972 0.90 CYP3A4 (0.60) CYP3A4FLT3RAB9ANPC1CYP2C9
SCHEMBL4355637 0.90 CYP3A4 (0.60) CYP3A4FLT3KDM4EPDE9ACYP2C9
SCHEMBL4354583 0.90 CYP3A4 (0.60) CYP3A4FLT3KDRCYP2C9MAPT
SCHEMBL4358437 0.88 CYP3A4 (0.59) CYP3A4FLT3POLBRAB9AKDM4E
SCHEMBL2019784 0.88 CYP3A4 (0.79) CYP3A4CYP2C9
SCHEMBL4356756 0.88 CYP3A4 (0.61) CYP3A4FLT3CYP2C9BTK
SCHEMBL4353817 0.88 CYP3A4 (0.58) CYP3A4FLT3CYP2C9BTK
SCHEMBL1128343 0.88 CYP3A4 (0.81) CYP3A4CYP2C9ALDH1A1SRCTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188098-B2 GPR119 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2012-05-29 US disclosed
US-20090286812-A1 GPR119 Receptor Agonists ERICKSON SHAWN DAVID 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286812-A1 GPR119 Receptor Agonists GPR119, GPR27, GPR139 CYP3A4 1503/4885FLT3 2186/4885POLB 4521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.